RespireRx Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for respiratory and neurological disorders. The company’s core expertise lies in its portfolio of ampakine compounds, which modulate AMPA receptors to enhance respiratory drive and cognitive function. RespireRx also advances cannabinoid prodrugs designed to address sleep-disordered breathing and related central nervous system indications.
Among RespireRx’s lead programs are the BHV-7000 series, which aims to provide rapid-onset respiratory stimulation in cases of opioid-induced respiratory depression, and BHV-4157, a prodrug of dronabinol engineered to treat sleep apnea and other respiratory conditions with improved pharmacokinetic properties. These candidates are supported by a series of patents and licenses originating from collaborations with academic institutions, including Duke University, where key ampakine technology was originally developed.
Founded in the mid-1990s as Cortex Pharmaceuticals, the company rebranded to RespireRx Pharmaceuticals in 2016 to reflect its strategic emphasis on respiratory care. Headquartered in the United States, RespireRx maintains research collaborations and seeks global partnerships to advance clinical development and commercialization of its product candidates across North America, Europe and other markets with significant unmet need in respiratory and neurological health.
RespireRx is led by a management team with deep experience in biopharmaceutical development. President and Chief Executive Officer Roger L. Hawley, Ph.D., brings a background in drug discovery and clinical program management, supported by executives in operations, regulatory affairs and business development who collectively drive the company’s efforts toward late-stage studies and potential out-licensing or commercialization agreements.
AI Generated. May Contain Errors.
